Chad Stewart joined Immatics in May 2017 and is responsible for directing the Program Management Team in Houston responsible for delivering the portfolio of T-Cell Programs currently in clinical development.
With over 24 years of industry experience, Chad has held numerous positions in R&D including quality control, clinical data management, clinical pharmacology, and most recently, project management. Chad contributed to the development of the oncology portfolio at GSK where he managed the global development program for Votrient® in renal-cell carcinoma. Chad also managed corporate development projects for Shire and contributed to multiple licensing and M&A deals. Most recently, as a Program Director at Merck, Chad led a team responsible for external clinical collaborations with Merck’s PD-1 inhibitor, Keytruda®.
Chad Stewart holds a Bachelor of Science in Biology, and a Master of Science in Microbiology from Thomas Jefferson University. Chad also holds an MBA from St. Joseph’s University.